Wu Yi, Sisi Lin, Rui Hao, Yiming Shao, Yannan Wang, Jin Yu, Lu Fang, Jingjing Zhu, Aiwei Wang, Yanfang Wu, Hua Huang, Chongyang Deng, Jingchao Sun, Hongcan Zhao, Ying Wang, Xiangming Tong
Allisartan isoproxil (AI) is an angiotensin II type 1 receptor blocker and be converted into the active substance EXP3174 in vivo. We evaluated the drug-drug interactions of AI and an indapamide sustained-release (Ind SR) preparation, as well as the pharmacokinetic characteristics and safety of AI and Ind SR in healthy subjects. The trial was set up in 6 sequences and 3 cycles, and each cycle contained a 7-day washout period. Subjects received 3 different trial drugs (A, AI; B, Ind SR; C, AI + Ind SR) during 3 different cycles...
October 10, 2023: Clinical Pharmacology in Drug Development